On CNBC’s Squawk on the Street, Jim Cramer had lots to say about various stocks and the new Trump administration. He reflected on industrialists and pharmaceutical companies that were sidelined recently and pointed out how the focus has shifted to tech leaders like Elon Musk. Cramer remarked, “Elon Musk has changed the equation,” highlighting the evolving landscape.
Cramer also brought up Musk’s influence in powerful sectors, questioning his presence in places like the Defense Department. He observed that if Musk wants to make an impact, he should aim for a more significant role—“I don’t want just a seat at the table; I want the table.”
During his discussion, Cramer addressed industries poised to gain from AI. He emphasized the importance of healthcare, noting that it will play a major role in AI’s future. Cramer warned that the sector isn’t fully developed and urged for a focus beyond improving call centers.
While markets were rising, Cramer pointed out that some areas remain stagnant. He stated, “There’s a considerable part of the market that has done nothing for years.” He expressed a lack of interest in small-cap stocks, suggesting they often disappoint, and instead, favors second-tier tech companies that show promise.
Cramer also had thoughts on President Trump’s role in addressing insurance costs. He suggested that the President should focus on pharmacy benefits managers to tackle inflation issues that affect many Americans. According to Cramer, these are significant areas needing attention.
“The President has to take a look at these issues. Because this is where the, the copay, your insurance, your group insurance, your property, casualty insurance. That’s where the President’s going to put it. If he wants to put a stake in the inflation. He goes after the pharmacy benefits managers.”
We compiled a list of stocks Cramer mentioned during the January 22nd episode of CNBC’s Squawk on the Street.
We also looked at hedge fund interest in these stocks. Research shows that mirroring top hedge fund picks can lead to better market performance. Our quarterly newsletter has returned 275% since May 2014, outperforming benchmarks significantly.
Marvell Technology, Inc. (MRVL): Delivering Custom AI Chips for Data Centers and AWS Trainium2
Marvell Technology, Inc. (NASDAQ:MRVL) designs chips for various applications, including signal processing and network solutions. Its stock has surged by 77% in the past year, largely due to excitement over custom AI processors. Cramer sees Marvell not as a competitor to NVIDIA but as a complementary player in big tech’s AI strategies. He highlighted Marvell as a “traveler” stock that has performed well recently.
“But then when you go to Marvell, now here’s a great example of what we’re talking about. Take Marvell Technology. Here’s a 108 billion dollar company. The CEO bought a billion dollars worth of stock; it was in the seventies, and now it’s at 125.”
MRVL is currently ranked 11th among the stocks Cramer discussed. While it shows promise, we believe there are even more exciting AI stocks that could offer greater returns in a shorter time frame.
READ NEXT: Check out the best AI stocks to buy now and a full list of AI companies with a market cap under $2 billion.
Disclosure: None. This content originally appeared on Insider Monkey.
